PDMR Dealings

Oxford Biomedica PLC

03 July 2023

 

PDMR Dealings

Oxford, UK - 3 July 2023: Oxford Biomedica plc ("Oxford Biomedica" or " the Company") (LSE:OXB), a quality and innovation-led viral vector CDMO, today announces that Non-Executive Directors Dr. Michael Hayden, Dr Heather Preston and Catherine Moukheibir have purchased ordinary shares in the Company pursuant to a trading plan put in place on 7 October 2022.   

By way of background, and as stated in the Oxford Biomedica 2021 Remuneration Policy which was approved at the 2021 Annual General Meeting, an additional fee of up to £50,000 per annum may be paid to any Non-Executive Director recruited from or based outside of the UK to reflect market levels of remuneration for Non-Executive Directors not based in the UK, subject to their agreement that the after tax amount of this additional fee will be used to acquire Oxford Biomedica shares at market value, which must be retained for at least 12 months from acquisition. The ordinary shares were all purchased at 430p and the number of ordinary shares purchased along with further information is set out in the table below:

Name of PDMR	Number of ordinary shares purchased	Number of ordinary shares now held	Total number of ordinary shares held as a percentage of the Company's share capital
Dr. Michael Hayden	6,684	17,973	0.019
Dr. Heather Preston	6,684	18,298	0.019
Cathrine Moukheibir	6,684	18,530	0.019

The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the number of ordinary shares purchased.

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")
a)	Name	Dr. Michael Hayden
2.	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Purchase of shares
c)	Currency	GBP - British pound
d)	Price(s) and volumes(s)	Price(s) Volume(s) £4.30 6,684
e)	Aggregated information -    Aggregate volume -    Aggregated total	6,684 £28,741.20
f)	Date of the transaction	2023-07-03
g)	Place of the transaction	London Stock Exchange, Main Market (XLON)

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")
a)	Name	Dr. Heather Preston
2.	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Purchase of shares
c)	Currency	GBP - British pound
d)	Price(s) and volumes(s)	Price(s) Volume(s) £4.30 6,684
e)	Aggregated information -    Aggregate volume -    Aggregated total	6,684 £28,741.20
f)	Date of the transaction	2023-07-03
g)	Place of the transaction	London Stock Exchange, Main Market (XLON)

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")
a)	Name	Catherine Moukheibir
2.	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Purchase of shares
c)	Currency	GBP - British pound
d)	Price(s) and volumes(s)	Price(s) Volume(s) £4.30 6,684
e)	Aggregated information -    Aggregate volume -    Aggregated total	6,684 £28,741.20
f)	Date of the transaction	2023-07-03
g)	Place of the transaction	London Stock Exchange, Main Market (XLON)

-Ends-

For further information, please contact:
Oxford Biomedica plc: Natalie Walter, Company Secretary	Tel: [phone]

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and a US-based subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn, Twitter and YouTube.

 

END